Cargando…

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

Liver fat deposition related to systemic insulin resistance defines non-alcoholic fatty liver disease (NAFLD) which, when associated with oxidative hepatocellular damage, inflammation, and activation of fibrogenesis, i.e. non-alcoholic steatohepatitis (NASH), can progress towards cirrhosis and hepat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dongiovanni, Paola, Anstee, Quentin M, Valenti, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850262/ https://www.ncbi.nlm.nih.gov/pubmed/23394097 http://dx.doi.org/10.2174/13816128113199990381

Ejemplares similares

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?
por: Eldafashi, Nardeen, et al.
Publicado: (2021)

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
por: Bianco, Cristiana, et al.
Publicado: (2021)

Genetics Is of the Essence to Face NAFLD
por: Meroni, Marica, et al.
Publicado: (2021)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Nutrition and Genetics in NAFLD: The Perfect Binomium
por: Meroni, Marica, et al.
Publicado: (2020)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
por: Dongiovanni, Paola, et al.
Publicado: (2015)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?
por: Dongiovanni, Paola, et al.
Publicado: (2013)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies
por: Heinemann, Fabian, et al.
Publicado: (2022)

A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
por: Dongiovanni, Paola, et al.
Publicado: (2017)

CDKN1A: A double-edged sword in fatty liver?
por: Valenti, Luca, et al.
Publicado: (2014)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

NAFLD-Associated HCC: Progress and Opportunities
por: Geh, Daniel, et al.
Publicado: (2021)

Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
por: Plaza-Díaz, Julio, et al.
Publicado: (2021)

Telomeres, NAFLD and Chronic Liver Disease
por: Donati, Benedetta, et al.
Publicado: (2016)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner
por: Chella Krishnan, Karthickeyan, et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
por: Liebig, Stephanie, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_33fobravif70seovl5fc8bm5k2